Tcr2 Therapeutics Inc

NASDAQ:TCRR   10:08:41 AM EDT
2.18
+0.02 (+0.93%)
Products

TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment

Published: 09/02/2021 13:27 GMT
Tcr2 Therapeutics Inc (TCRR) - Tcr² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma.